IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth
IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX
Microsoft, AbbVie and BHP anchor today???s top analyst reports, highlighting AI growth, drug pipeline strength and rising commodity output shaping outlooks.
Zacks
Top Analyst Reports for Microsoft, AbbVie & BHP
Microsoft rides AI and Azure growth, but slowing cloud guidance, capacity limits, and rising competition cast a shadow on its momentum.
Zacks
Iridex's Q4 Loss Narrows Year Over Year on Retina Sales Growth
IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.
Zacks Initiates Coverage of Iridex With Neutral Recommendation
Discover why Zacks initiated coverage of IRIX with a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Learn how global sales momentum and stronger liquidity are balanced against margin pressures and dependency on a key distributor.